Treatment Refractory MAC Lung Disease clinical trials at UCSF
1 research study open to eligible people
Treatment refractory MAC lung disease is a condition where lung infections persist despite treatment. UCSF is examining the effectiveness of Clofazimine delivered through inhalation. The clinical trial checks how well the medicine works and its safety for people with persistent lung infections.
Showing trials for
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
open to eligible people ages 18-85
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Fresno, California and other locations
Our lead scientists for Treatment Refractory MAC Lung Disease research studies include Mohamed Fayed, MD, FCCP.
Last updated: